La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

  • ID: 3783272
  • Company Profile
  • 39 pages
  • Global Markets Direct
  • La Jolla Pharmaceutical Company
1 of 3
La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

Summary

‘La Jolla Pharmaceutical Company - Product Pipeline Review - 2016’, provides an overview of the La Jolla Pharmaceutical Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of La Jolla Pharmaceutical Company
- The report provides overview of La Jolla Pharmaceutical Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses La Jolla Pharmaceutical Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features La Jolla Pharmaceutical Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate La Jolla Pharmaceutical Company’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for La Jolla Pharmaceutical Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding La Jolla Pharmaceutical Company’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

La Jolla Pharmaceutical Company Snapshot

La Jolla Pharmaceutical Company Overview

Key Information

Key Facts

La Jolla Pharmaceutical Company - Research and Development Overview

Key Therapeutic Areas

La Jolla Pharmaceutical Company - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

La Jolla Pharmaceutical Company - Pipeline Products Glance

La Jolla Pharmaceutical Company - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

La Jolla Pharmaceutical Company - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products

Unknown Products/Combination Treatment Modalities

La Jolla Pharmaceutical Company - Drug Profiles

LJPC-501

Product Description

Mechanism of Action

R&D Progress

LJPC-401

Product Description

Mechanism of Action

R&D Progress

LJPC-0712

Product Description

Mechanism of Action

R&D Progress

LJPC-30Sa

Product Description

Mechanism of Action

R&D Progress

LJPC-30Sb

Product Description

Mechanism of Action

R&D Progress

LJPC-6417

Product Description

Mechanism of Action

R&D Progress

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva

Product Description

Mechanism of Action

R&D Progress

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders

Product Description

Mechanism of Action

R&D Progress

Drugs for Undisclosed Indications

Product Description

Mechanism of Action

R&D Progress

La Jolla Pharmaceutical Company - Pipeline Analysis

La Jolla Pharmaceutical Company - Pipeline Products by Target

La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration

La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type

La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action

La Jolla Pharmaceutical Company - Recent Pipeline Updates

La Jolla Pharmaceutical Company - Dormant Projects

La Jolla Pharmaceutical Company - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

GCS-100

LJPC-1010

La Jolla Pharmaceutical Company - Company Statement

La Jolla Pharmaceutical Company - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

La Jolla Pharmaceutical Company, Key Information

La Jolla Pharmaceutical Company, Key Facts

La Jolla Pharmaceutical Company - Pipeline by Indication, 2016

La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016

La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016

La Jolla Pharmaceutical Company - Phase III, 2016

La Jolla Pharmaceutical Company - Phase I, 2016

La Jolla Pharmaceutical Company - Preclinical, 2016

La Jolla Pharmaceutical Company - Discovery, 2016

La Jolla Pharmaceutical Company - Unknown, 2016

La Jolla Pharmaceutical Company - Pipeline by Target, 2016

La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016

La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016

La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016

La Jolla Pharmaceutical Company - Recent Pipeline Updates, 2016

La Jolla Pharmaceutical Company - Dormant Developmental Projects,2016

La Jolla Pharmaceutical Company - Discontinued Pipeline Products, 2016

La Jolla Pharmaceutical Company, Subsidiaries

List of Figures

La Jolla Pharmaceutical Company - Pipeline by Top 10 Indication, 2016

La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016

La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016

La Jolla Pharmaceutical Company - Pipeline by Target, 2016

La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016

La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016

La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll